Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever (FMF)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01705756 |
Recruitment Status :
Completed
First Posted : October 12, 2012
Last Update Posted : July 21, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
FMF is the most common periodic fever with a worldwide patient population estimated as 150,000, mainly located in the Eastern Mediterranean basin. colchicine is the established therapy of choice ,however, around 20.000 patients worldwide fail to respond or cannot tolerate therapeutic doses, thereby suffering from recurrent debilitating, severe, painful attacks of peritonitis, pleuritis and synovitis and are at risk to die from reactive amyloidosis .Mutation-induced reduction in pyrin/ marenostrin activity is thought to underlie the disease by leading to NALP3 inflammasome activation ,and thereby to IL-1β related burst of inflammation.
The IL-1 receptor antagonist Kineret (Anakinra), seems to be the most appropriate response to the uncontrolled IL-1β elevation. Indeed, an increasing number of reports over the last few years indicate a good response to Kineret (Anakinra), in colchicine-resistant FMF ,also in children ,however, no controlled study has thoroughly evaluated the efficacy and safety of this treatment.
Study outline:
The study aims to run at the FMF centre in Sheba Medical Center, covering more than 10,000 patients. The study will evaluate the effect of recombinant IL-1 receptor antagonist, Kineret (Anakinra), on the frequency of FMF attacks in patients that, despite maximum tolerable dose of colchicine, present with more than one attack per month.
The study is designed as a randomised, placebo-controlled, double-blind study. 50 patients will be randomised to treatment with either Kineret (Anakinra), or placebo treatment for 4 months.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Familial Mediterranean Fever | Drug: Kineret | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 25 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Randomized Placebo-Controlled Study of the Efficacy and Safety of Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever |
Study Start Date : | November 2012 |
Actual Primary Completion Date : | December 2014 |
Actual Study Completion Date : | June 2015 |

Arm | Intervention/treatment |
---|---|
Placebo Comparator: Vehicle
•Patients randomized to placebo will receive syringes identical to active drug (100 mg prefilled syringes for subcutaneous injection) filled with drug vehicle
|
Drug: Kineret
Patients randomized to active drug will receive Kineret(Anakinra), 100 mg prefilled syringes for subcutaneous injection, once a day for 4 months. The syringes will arrive relabeled from the supplier (SOBI) to Sheba Medical Center. They will be stored at the PI's store room in a temperature controlled refrigerator.
Other Name: Anakinra |
Experimental: Kineret (Anakinra)
Patients randomized to active drug will receive Kineret (Anakinra), 100 mg prefilled syringes for subcutaneous injection, once a day for 4 months. The syringes will arrive relabeled from the supplier (SOBI) to Sheba Medical Center. They will be stored at the PI's store room in a temperature controlled refrigerator.
|
Drug: Kineret
Patients randomized to active drug will receive Kineret(Anakinra), 100 mg prefilled syringes for subcutaneous injection, once a day for 4 months. The syringes will arrive relabeled from the supplier (SOBI) to Sheba Medical Center. They will be stored at the PI's store room in a temperature controlled refrigerator.
Other Name: Anakinra |
- Number of patients with less than a mean of one FMF attack per month [ Time Frame: 4 months ]Total number of FMF attacks in abdominal, thoracic, skin or joint locations during the observational period (4 months) as recorded in the patient diary, devided by 4 for each patient will result in number of attacks per one month. The number of patients with less than 1 attack per month will be compared between the 2 study groups
- Number of serious adverse events [ Time Frame: 4 months ]
Secondary endpoint is defined as total number of serious adverse events per 4 months in each study group. SAE is defined as an adverse event that meets one or more of the following criteria/outcomes:
- Death
- Life-threatening (i.e., at immediate risk of death)
- In-patient hospitalization or prolongation of existing hospitalization
- Persistent or significant disability/incapacity
- Congenital anomaly/birth defect

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
A subject must fulfil the following criteria in order to be included in the study:
- FMF diagnosed as per the Tel-Hashomer criteria -(Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum.1998 Aug; 41(8):1516-7-Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, Migdal A, Padeh S, Pras M).
- 18-65 years of age
- Verified as mutations in both alleles of the MEFV gene, thus including homozygous and compound heterozygous patients
- Patient compliant with maximum tolerable dose of colchicine (up to 3 mg/day)
- At least one FMF attack per month in chest, abdomen or joints (definition of attack see above)
- Adequate contraception for sexually active male and female patients
Exclusion Criteria:
The presence of any of the following will exclude a subject from inclusion in the study:
- Patient pregnant at enrolment visit
- Prior or existing malignancy
- Active infection
- Manifest renal failure with Creatinine clearance <30mL/min as determined by the equation Creatinine clearance (ml/min) = (140-age) x Wight (Kg) /72 x serum creatinine (mg/dcl) For women one should multiply the results by 0.8
- Live vaccinations last three months before enrolment
- Sociopsychological state threatening compliance with the treatment protocol
- Alcohol or substance abuse
- Concomitant medication with biological or anti-rheumatic disease-modifying drugs or systemic steroids
- Any prior use of IL-1 inhibitory drugs
-
Associated disease that could interfere with clinical assessment:
- Rheumatic disorder
- Systemic disease, e.g. autoimmune or other autoinflammatory disorder, diabetes, hypertension, vasculitis, Behçet's disease
- Gastrointestinal disorder, e.g. Crohn's disease, ulcerative colitis, irritable bowel syndrome
- Cardiovascular disorder, e.g. post myocardial infarction, angina
- Pulmonary disorder, e.g. COPD, pulmonary hypertension
- Any other condition which in the opinion of the investigator makes the subject unsuitable for inclusion
- Enrolment in another concurrent clinical study, or intake of an investigational drug, within three months prior to inclusion in this study
-
Failure or refusal to cooperate with given instructions
-

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01705756
Israel | |
Sheba Medical Center | |
Tel- Hashomer, Ramat- Gan, Israel, 52621 |
Principal Investigator: | Avi Livneh, professor | Sheba Medical Center, Tel- Hashomer, Ramat- Gan, Israel. |
Responsible Party: | Prof.Avi Livneh, Principal Investigator, Head of Internal Medicine "F" , Director of national center of FMF, Israel, Sheba Medical Center |
ClinicalTrials.gov Identifier: | NCT01705756 |
Other Study ID Numbers: |
SHEBA-11-8557-AL-CTIL |
First Posted: | October 12, 2012 Key Record Dates |
Last Update Posted: | July 21, 2017 |
Last Verified: | July 2017 |
Colchicine Anakinra Colchicine resistance Familial Mediterranean fever |
Brucellosis Familial Mediterranean Fever Hereditary Autoinflammatory Diseases Fever Body Temperature Changes Gram-Negative Bacterial Infections Bacterial Infections |
Bacterial Infections and Mycoses Infections Genetic Diseases, Inborn Skin Diseases, Genetic Skin Diseases Interleukin 1 Receptor Antagonist Protein Antirheumatic Agents |